Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs

Michael F. Powell; Donna J. Eastman; Amy Lim; Catherine Lucas; Michael Peterson; Joann Vennari; Robert P. Weissburg; Terri Wrin; Charlotte R. Kensil; Mark J. Newman; Jack Nunberg; Jeffrey L. Cleland; Tim J. Gregory; Phillip W. Berman

doi:10.1089/aid.1995.11.203

Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs

Michael F. Powell, Donna J. Eastman, Amy Lim, Catherine Lucas, Michael Peterson, Joann Vennari, Robert P. Weissburg, Terri Wrin, Charlotte R. Kensil, Mark J. Newman, Jack Nunberg, Jeffrey L. Cleland, Tim J. Gregory, Phillip W. Berman

Montana Biotechnology Center

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21 formulations than in animals immunized with the other adjuvants, and correlated well with higher virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.

Original language	English
Pages (from-to)	203-209
Number of pages	7
Journal	AIDS Research and Human Retroviruses
Volume	11
Issue number	2
DOIs	https://doi.org/10.1089/aid.1995.11.203
State	Published - Feb 1995

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/aid.1995.11.203

Cite this

Powell, M. F., Eastman, D. J., Lim, A., Lucas, C., Peterson, M., Vennari, J., Weissburg, R. P., Wrin, T., Kensil, C. R., Newman, M. J., Nunberg, J., Cleland, J. L., Gregory, T. J., & Berman, P. W. (1995). Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs. AIDS Research and Human Retroviruses, 11(2), 203-209. https://doi.org/10.1089/aid.1995.11.203

@article{1ca9b8892de44bf5bcbb5baff63c5525,

title = "Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs",

abstract = "The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21 formulations than in animals immunized with the other adjuvants, and correlated well with higher virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.",

author = "Powell, \{Michael F.\} and Eastman, \{Donna J.\} and Amy Lim and Catherine Lucas and Michael Peterson and Joann Vennari and Weissburg, \{Robert P.\} and Terri Wrin and Kensil, \{Charlotte R.\} and Newman, \{Mark J.\} and Jack Nunberg and Cleland, \{Jeffrey L.\} and Gregory, \{Tim J.\} and Berman, \{Phillip W.\}",

year = "1995",

month = feb,

doi = "10.1089/aid.1995.11.203",

language = "English",

volume = "11",

pages = "203--209",

journal = "AIDS Research and Human Retroviruses",

issn = "0889-2229",

publisher = "Mary Ann Liebert Inc.",

number = "2",

}

TY - JOUR

T1 - Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs

AU - Powell, Michael F.

AU - Eastman, Donna J.

AU - Lim, Amy

AU - Lucas, Catherine

AU - Peterson, Michael

AU - Vennari, Joann

AU - Weissburg, Robert P.

AU - Wrin, Terri

AU - Kensil, Charlotte R.

AU - Newman, Mark J.

AU - Nunberg, Jack

AU - Cleland, Jeffrey L.

AU - Gregory, Tim J.

AU - Berman, Phillip W.

PY - 1995/2

Y1 - 1995/2

N2 - The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21 formulations than in animals immunized with the other adjuvants, and correlated well with higher virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.

AB - The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21 formulations than in animals immunized with the other adjuvants, and correlated well with higher virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.

UR - https://www.scopus.com/pages/publications/0029141671

U2 - 10.1089/aid.1995.11.203

DO - 10.1089/aid.1995.11.203

M3 - Article

C2 - 7742035

AN - SCOPUS:0029141671

SN - 0889-2229

VL - 11

SP - 203

EP - 209

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

IS - 2

ER -

Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this